Peptide Skincare & BeautySkin science and ingredient guides

Skin science article

GHK-Cu (100 mg Vial) Dosage Chart - Peptide Dosages

GHK-Cu (100mg Vial) Dosage Protocol Copper tripeptide for skin remodeling/repair — research/educational dosing reference. Mix & measure GHK-Cu · 100 mg Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run y

GHK-Cu (100mg Vial) Dosage Protocol

Copper tripeptide for skin remodeling/repair — research/educational dosing reference.

Mix & measure GHK-Cu · 100 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Dosing & Reconstitution Guide

A single practical dilution with accurate dosing, step by step

Standard / Conservative Approach (3 mL = ~33.3 mg/mL; 5 days/week)

Reconstitute: Add 3.0 mL bacteriostatic water to one 100 mg vial → final concentration ~33.3 mg/mL (33,300 mcg/mL).

Typical range: 1.0–2.0 mg per injection, raised gradually over an 8–12 week course; start low to gauge tolerance.

Easy measuring: At ~33.3 mg/mL, 1 unit ≈ 0.333 mg on a U-100 syringe. For doses of 10 units or less, a 30- or 50-unit insulin syringe improves readability.

Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.

The reference edit

Ingredients, questions
& further reading.

Connected source records selected through this article’s public topic index.

01

Formula cabinet

Ingredients & structured notes

02

Product index

Related product references

Product

Lovely Southern GHK-Cu Repair Serum

Lovely Southern GHK-Cu Repair Serum Ingredients in Lovely Southern GHK-Cu Repair Serum explained: benefits, concerns, and detailed analysis of 9 ingredients including Water, Sodium Hyaluron…

Source: skinsort.comView reference →
03

Comparison edit

Read side by side

Copper Peptide vs the Field

Primary target Tissue remodeling, ECM Telomerase, pineal Mitochondria, metabolism Structure Tripeptide + Cu²⁺ Tetrapeptide 16-mer MDP Topical effective Yes No Gene modulation ~4,000 genes L…

GHK-Cu 60s Age Specific Protocol: Administration Method Comparison

Subcutaneous (abdominal) 60–75% 45–90 minutes 8–12 hours Once daily Highest consistency in absorption and plasma levels; preferred for structured protocols requiring reproducible dosing Tra…

04

Ask the journal

Related questions

01What If My Hair Loss Is Advanced — Will GHK-Cu Still Work?

Probably not as a standalone intervention. GHK-Cu requires viable follicle stem cells in the bulge region to anchor the basement membrane it's trying to rebuild. In Norwood V–VII androgenetic alopecia, most follicles are terminally miniaturized. The stem cell niche is gone. Minoxidil can sometimes stimulate regrowth in advanced cases through sheer perfusion increase, even when the follicle structure is compromised. GHK-Cu is better suited for early-to-moderate thinning (Norwood II–IV) where the follicle architecture is damaged but not destroyed.

Source · realpeptides.co
02What If the Lyophilized GHK-Cu Powder Arrived as White or Pale Yellow Instead of Blue?

Contact the supplier immediately—this indicates either incorrect product or degraded peptide. Intact GHK-Cu with chelated copper(II) is blue to blue-violet due to d-d electronic transitions in the copper coordination complex. White powder suggests the peptide is present without copper (it wasn't properly chelated during synthesis), and pale yellow suggests copper has oxidized to Cu(I) or dissociated entirely. Neither variant provides the intended biological activity. Lyophilized GHK CU Cosmetic 5MG should always arrive as a distinctly blue powder—color is the first quality indicator before reconstitution.

Source · realpeptides.co
03What If Cell Lines Show No Response to GHK-Cu Despite Adequate Dosing?

Confirm integrin α2β1 expression in your cell line using flow cytometry or Western blot. Not all fibroblasts or endothelial lines express this receptor at functional levels. Primary dermal fibroblasts and human umbilical vein endothelial cells (HUVECs) are positive controls; immortalized lines like NIH-3T3 or transformed keratinocyte lines may lack integrin expression entirely. If integrin is confirmed present, test a concentration range from 1 nanomolar to 10 micromolar. The dose-response curve is non-monotonic, and suboptimal dosing produces no effect. Serum concentration in culture media also matters: 10% FBS contains enough albumin to sequester free copper and reduce bioavailable GHK-Cu by 50%, so dose accordingly.

Source · realpeptides.co
04What If GHK-Cu Is Combined with UV Exposure or Oxidative Stressors?

GHK-Cu downstream effects are amplified under oxidative stress conditions because Nrf2 pathway activation is stress-responsive. UV-exposed keratinocytes show 2–3× greater SOD upregulation in response to GHK-Cu compared to unstressed cells. The practical implication: pre-treatment with GHK-Cu before UV exposure (or other oxidative insults) provides greater downstream protection than post-exposure application. The peptide primes the antioxidant response system, not just repairs damage after the fact.

Source · realpeptides.co
05What If the Supplier Provides a CoA But Won't Share the HPLC Chromatogram?

Request the raw chromatogram file directly. Legitimate suppliers provide it without hesitation because the data supports their purity claims. If the supplier resists or claims the chromatogram is proprietary, the CoA is likely fabricated or the material wasn't tested independently. HPLC chromatograms show retention time, peak shape, and baseline noise. All of which verify whether the stated purity matches the actual separation profile. A CoA without the underlying chromatogram is a summary with no audit trail.

Source · realpeptides.co
05

Source shelf

Research & excerpts

Research note

The Current State of GHK-Cu Clinical Trials 2026: A Snapshot

Navigating the current clinical trial landscape can be daunting. There are dozens of studies, each with its own specific focus, methodology, and phase. Our team has compiled a brief overview to help contextualize the ongoing work. It's important to remember that 'clinical trial' encompasses a broad spectrum, from preliminary safety assessments to large-scale efficacy studies. The journey from bench to bedside is a grueling road warrior hustle, demanding impeccable data and unwavering commitment. | Trial Phase | Primary Objective | Current Focus (2026) GHK-Cu clinical trials 2026 are poised to redefine the applications of this peptide. It's a truly a captivating time for peptide research, and we're excited to contribute to the global scientific community by providing the highest quality research materials. We stand behind every product we sell, ensuring you have a trusted partner in your research. We encourage you to explore our full range of high-purity research peptides and discover premium peptides for research that can elevate your work.

Source · realpeptides.co

Research note

Controlled Clinical Trials in Wound Management

Multiple controlled clinical trials have evaluated GHK-Cu efficacy in chronic wound management, with generally positive outcomes across various wound etiologies. A randomized, double-blind trial published in the Journal of Wound Care examined 82 patients with diabetic foot ulcers treated with either GHK-Cu-containing hydrogel dressing (1% concentration) or placebo gel over 12 weeks. Results demonstrated significantly improved healing rates in the GHK-Cu group, with 64% achieving complete wound closure compared to 38% in the placebo group (p<0.01). Time to 50% wound area reduction was also significantly shorter in GHK-Cu-treated patients (4.2 weeks vs. 6.8 weeks, p<0.05). Similar benefits have been documented in venous leg ulcer populations, where GHK-Cu-containing compression systems produced 30-40% greater reductions in ulcer area compared to compression therapy alone over 8-12 week treatment periods. A meta-analysis incorporating data from five controlled trials encompassing 312 chronic wound patients concluded that GHK-Cu-based treatments increase the probability of complete healing by approximately 40% (relative risk 1.42, 95% CI 1.18-1.71) compared to standard wound care alone. These clinical benefits appear most pronounced in wounds with impaired healing due to ischemia, chronic inflammation, or advanced patient age, where GHK-Cu's multi-mechanistic effects on angiogenesis, inflammation, and matrix synthesis provide comprehensive therapeutic support.

Source · deltapeptides.com